It has been announced that following Bristol-Myers Squibb’s (BMS) successful acquisition of Amylin Pharmaceuticals, AstraZeneca (AZ) has made an initial payment of approximately US $3.2 billion ...
Bristol-Myers Squibb Co. has announced it will acquire Amylin Pharmaceuticals for approximately US $5.3 billion in cash. Following the completion of this acquisition, Bristol-Myers Squibb will ...
The Gubra drug a peptide engineered to be an analog for amylin, a hormone that helps regulate blood sugar and food intake. It is specifically designed to bind to and activate amylin and calcitonin ...
GUB014295 is currently in a phase 1 clinical trial. A potential long-acting amylin analog, GUB014295 is an agonist that specifically activates amylin and calcitonin receptors. Amylin, a satiety ...
AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity
GUB014295 is currently in a Phase 1 clinical trial. A potential long-acting amylin analog, GUB014295 is an agonist that specifically activates amylin and calcitonin receptors. Amylin, a satiety ...
AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity
Partnership marks AbbVie's entrance into the obesity field Agreement will enable the incorporation of GUB014295, an amylin peptide discovered and developed by Gubra, into AbbVie's global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback